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Abstract
Aims/hypothesis We investigated whether skeletal muscle per-
oxisome proliferator-activated receptor gamma coactivator-1
(PGC1A; also known asPPARGC1A) and its target mitofusin-2
(MFN2), as well as carnitine palmitoyltransferase-1 (CPT1;
also known as carnitine palmitoyltransferase 1A [liver]
[CPT1A]) and uncoupling protein (UCP)3, are involved in
the improvement of insulin resistance and/or in the modifica-
tion of energy expenditure during surgically induced massive
weight loss.
Materials and methods Seventeen morbidly obese women
(mean BMI: 45.9±4 kg/m2) were investigated before, and 3
and 12 months after, Roux-en-Y gastric bypass (RYGB). We
evaluated insulin sensitivity by the euglycaemic–hyperinsu-
linaemic clamp, energy expenditure and substrate oxidation
by indirect calorimetry, and muscle mRNA expression by
PCR.
Results Post-operatively, PGC1A was enhanced at 3 ( p=
0.02) and 12 months ( p=0.03) as was MFN2 ( p=0.008 and
p=0.03 at 3 and 12 months respectively), whereas UCP3
was reduced ( p=0.03) at 12 months. CPT1 did not change.
The expression of PGC1A and MFN2 were strongly ( p<
0.0001) related. Insulin sensitivity, which increased after
surgery ( p=0.002 at 3, p=0.003 at 12 months), was sig-
nificantly related to PGC1A and MFN2, but only MFN2
showed an independent influence in a multiple regression
analysis. Energy expenditure was reduced at 3 months post-
operatively ( p=0.001 vs before RYGB), remaining un-
changed thereafter until 12 months. CPT1 and UCP3 were
not significantly related to the modifications of energy ex-
penditure or of lipid oxidation rate.
Conclusions/interpretation Weight loss upregulates PGC1A,
which in turn stimulates MFN2 expression. MFN2 expres-
sion significantly and independently contributes to the im-
provement of insulin sensitivity. UCP3 and CPT1 do not
seem to influence energy expenditure after RYGB.
Keywords CPT1 . Insulin sensitivity .MFN2 .PGC1A .
PPARGC1A . Roux-en-Y gastric bypass .
UCP3 . Weight loss
Abbreviations
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Introduction
Skeletal muscle mitochondrial function is impaired in obese
and in diabetic patients [1], and this may contribute to the
development of insulin resistance [2]. In turn, insulin re-
sistance contributes to obesity-related co-morbidities, such as
type 2 diabetes and cardiovascular diseases [3]. Thus, the
correction of excess body weight and insulin resistance is of
primary importance in the prevention of pathologies linked
to obesity.
Bariatric surgery is the elective treatment for morbid
obesity, with Roux-en-Y gastric bypass (RYGB) accounting
for more than 80% of all bariatric interventions [4]. It
induces a large and durable weight reduction as well as a
substantial amelioration of insulin resistance [5].
Despite the large number of RYGB operations performed,
the metabolic and molecular determinants of improved insulin
sensitivity and of body weight loss are not well known.
Among the numerous candidates potentially involved in
the amelioration of insulin sensitivity, we focused on the per-
oxisome proliferator activated receptor gamma-coactivator-1
(PGC1A) and some of its known transcriptional targets.
PGC1A and its target mitofusin-2 (MFN2) are both
involved in mitochondrial biogenesis and in the maintenance
of the mitochondrial network [6–8]. Moreover, MFN2 aug-
ments mitochondrial oxidative capacity for both glucose and
lipids [9] and PGC1A increases expression of the insulin-
sensitive glucose transporter 4 [10]. Thus, PGC1A and
MFN2 could both enhance insulin sensitivity.
PGC1A and MFN2 are altered in patients with obesity and
type 2 diabetes [11, 12], conditions that are both charac-
terised by intense insulin resistance. On the other hand, these
factors are upregulated by physical exercise [7, 13], a sit-
uation which is known to ameliorate insulin sensitivity [14].
It is therefore reasonable to hypothesise that PGC1A and
MFN2 could be involved in the improvement of insulin
sensitivity induced by weight loss.
Another PGC1A target is carnitine palmitoyltransferase-1
(CPT1) [15], the main regulator of long-chain fatty acids
transport across the mitochondrial membrane [16]. A defect
in CPT1 has been observed in muscle of obese persons [17],
persisting after weight loss [18]. Defective lipid oxidation,
resulting from impaired CPT1 activity, could lead to exces-
sive intramyocellular triacylglycerol accumulation and, ul-
timately, to insulin resistance [17]. Furthermore, after weight
loss, a low lipid oxidation rate could favour relapse to
obesity [18].
We have previously demonstrated that during RYGB-
induced weight loss an energy economy mechanism, based
on low lipid oxidation, hampers the process of body weight
loss [19]. Thus, we hypothesised that a defect in CPT1
could influence energy expenditure and/or lipid oxidation
after RYGB.
The uncoupling protein (UCP) family is a group of
proteins that contribute to the regulation of lipid oxidation
[20]. Therefore, UCPs could play an important role in the
regulation of energy expenditure [21]. We previously dem-
onstrated that, when body weight is stable, UCP3 expres-
sion in the skeletal muscle of obese participants is not
significantly related to the basal metabolic rate [22]. How-
ever, the decreased UCP3 expression repeatedly reported in
post-obese patients [23–25] suggests that, during the weight
loss process, downregulation of UCP3 could lead to energy
conservation, thus limiting the extent of weight loss. There-
fore, UCP3 is a potential determinant of energy expenditure
during weight loss.
In the present study, we studied the change in skeletal
muscle expression of PGC1A (also known as PPA-
RGC1A), MFN2, CPT1 (also known as carnitine palmitoyl-
transferase 1A [liver] [CPT1A]) and UCP3 during
surgically induced massive weight loss. Our aim was to
investigate whether one or more of these factors are involved
in the improvement of insulin sensitivity and/or in the
modifications of energy expenditure associated with surgical-
ly induced weight loss. Two post-operative time-points, 3 and
12 months, were selected because they are representative of
the rapid and slow phases of body weight loss induced by
RYGB, as previously described [26].
Materials and methods
Participants A group of 17 morbidly obese normotensive
women (mean age 39±11 years) participated in the study.
Ten of these had normal fasting plasma glucose (i.e.
<6.0 mmol/l), four impaired fasting glucose (i.e. 6.0–
6.9 mmol/l) and three had type 2 diabetes (i.e. fasting
plasma glucose ≥7 mmol/l) not treated with insulin. The
participants were studied before and 3 months after RYGB.
Eleven of the participants also agreed to undergo the same
tests 12 months after the operation. At this last time-point,
the euglycaemic–hyperinsulinaemic clamp was not done in
one patient for technical reasons. This study was approved
by the Ethical Committee of the Department of Surgery of
the Geneva University Hospital. The patients were in-
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formed about the aims of the study and gave their written
consent.
Surgical procedure RYGB is a surgical procedure whereby a
small stomach pouch is first separated from the distal stom-
ach. Following this, a Y-shaped section of the small intestine
is connected to the gastric pouch in order to bypass the
duodenum and a part of the jejunum. Finally, this bypassed
portion of the intestine is attached more distally to the small
bowel [27]. This surgical procedure induces weight loss by
both a restrictive (i.e. stomach volume reduction) and a
malabsorptive (i.e. the bypass of the duodenum and a part of
the jejunum) mechanism.
Experimental protocol The patients were admitted to
hospital in the morning (08:00 hours), after an overnight
fasting period (10–12 h). First, body weight, height and
body composition were measured. After voiding, venous
catheters were inserted into a dorsal vein of the hand and
into the left antecubital vein of the contra-lateral arm (for
blood sampling and infusion of all test substances respec-
tively). Indirect calorimetry was performed for 30 min in
basal fasting conditions and repeated throughout the last
30 min of the euglycaemic–hyperinsulinaemic clamp. After
the first calorimetric measurement, a skeletal muscle sample
was taken for biopsy; then the patient underwent a 2 h
euglycaemic–hyperinsulinaemic clamp. At the end of the tests
urine was collected in order to measure urinary nitrogen.
Anthropometric measurements Body weight was measured
using a Lindel balance scale (Samhald, Klippan, Sweden)
while the participant wore only underclothes and no shoes.
Height wasmeasured at the same time. Body composition was
measured using a body impedance analyser (Nutriguard-M,
Darmstadt, Germany), with the electrodes placed on the right
hand and foot. Lean body mass (LBM) was calculated
according to Segal [28].
Indirect calorimetry For this test, patients were asked not to
perform intense physical activity for 48 h before the test and
also to avoid smoking. For the 3 days preceding the test, they
were also advised to consume a balanced diet, consisting of
about 40% of energy as carbohydrate, 30% as lipid and 30%
as protein, without any modification of their usual energy
intake. The patients were placed in a recumbent position with
the head in a ventilated hood (Deltatrac; Datex, Helsinki,
Finland) and oxygen consumption (V
 O2) and carbon dioxide
production (V
 CO2) were measured. After a 15 min equili-
bration period, gas exchange was measured for 30 min and
used to calculate the respiratory quotient as well as glucose
and lipid oxidation rates, according to Ferrannini [29]. Pro-
tein oxidation was calculated as 6.235×N [30], where N is
nitrogen excretion (mg/min) in urine measured by spectro-
photometry. The lipid and protein oxidation rates are
expressed as mg kg LBM−1 min−1. Glucose oxidation is ex-
pressed as μmol kg LBM−1 min−1. Resting energy expendi-
ture was calculated from the rates of substrate oxidation and
expressed in MJ/day. The respiratory exchange rate (RER)
was calculated as the ratio between V
CO2 and V O2.
Euglycaemic–hyperinsulinaemic clamp procedure Insulin
sensitivity was evaluated by the euglycaemic–hyperinsulinae-
mic clamp procedure [31]. After a priming dose (0.8 U/m2 of
body surface area over 10 min), the patients received a
constant infusion of insulin at the rate of 0.04 U m−2 min−1
throughout the test. The overall duration of the test was
120 min. A 200 g/l glucose solution was infused at variable
rates in order to maintain glycaemia at a constant level of
5.0 mmol/l. Whole-body glucose uptake, expressed in μmol
kg LBM−1 min−1, was calculated during the last 40 min
period of the test, when glucose infusion reached steady
state. The insulin-induced modifications of substrate oxida-
tive rate were calculated as the differences between the
values measured during the clamp and those measured in
basal conditions (Δ from baseline).
Blood chemistry Plasma glucose was determined enzymati-
cally using an automated glucose analyser (Beckman Coulter,
Fullerton, CA, USA). Insulin concentrations were measured
by radioimmunoassay, using a commercial kit (Linco Re-
search, St Charles, MI, USA).
Muscle biopsy sampling, treatment and analysis Skeletal
muscle samples were obtained under local anaesthesia from
the belly of the vastus lateralis muscle using a percutaneous
needle biopsy technique modified to include suction. A single
incision was made in the skin and two muscle samples were
taken from a single insertion of the biopsy needle. After the
first biopsy cut, the needle was rotated and a second cut was
performed. Each muscle sample weighed between 50 and
80 mg. The muscle sample was immediately frozen in liquid
nitrogen and used for RNA extraction.
RNA extraction from muscle biopsies and real-time quan-
titative PCR Total RNA was extracted from ∼40 mg frozen
muscle portions by the guanidinium isothiocyanate acid
phenol procedure, after which 3 μg of RNA was reverse-
transcribed to cDNA as reported previously [32]. Quanti-
tative PCR was performed using a thermal cycler system
(MX3000p; Roche Diagnostics, Rotkreuz, Switzerland)
with gene-specific primers as reported previously [32]. To
control for any variations due to efficiencies of the reverse
transcription and PCR, ribosomal 28S was used as an in-
ternal control. Leptin mRNA was also measured in the
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muscle samples to control for any potential contamination
by fat tissue in the biopsies. All PCR runs were performed
in triplicate.
Statistics Values are given as means±SD. The non-parametric
Wilcoxon signed-rank test was used for comparisons before
and after RYGB. Since at 12 months 11 patients were in-
vestigated, of whom only ten could perform the euglycaemic
clamp, the Wilcoxon test was applied to the 11 pairs of values
for mRNA expression and to the ten pairs of values for the
glucose uptake. Simple and multiple regression analyses
were used to examine associations and to identify the best
predictors of the investigated variables. The threshold of
significance was set at p<0.05. Statistical analyses were
performed by a computerised program (Statview 4; Abacus
Concepts, Berkeley, CA, USA).
Results
The change in body weight and BMI is illustrated in Table 1,
as well as the significant decrease of fasting glucose and
insulin plasma levels.
Energy expenditure (MJ/day) was reduced at 3 months
and remained so at 12 months (Table 1). Protein oxidation
was decreased 3 months ( p=0.001) after surgery, returning
to pre-operative values at 12 months. Fasting glucose
oxidation was not statistically significantly reduced at
3 months ( p=0.08), but the reduction reached statistical
significance at 12 months ( p<0.05). Lipid oxidation was
not significantly changed after surgery.
Figure 1a shows that skeletal muscle PGC1A mRNAwas
increased both at 3 and 12 months compared with pre-
operative values (p=0.02 and p=0.03, respectively). Muscle
MFN2 mRNA (Fig. 1b) was also increased ( p=0.008 at
3 months, p=0.03 at 12 months after surgery). There was no
significant modification of CPT1 mRNA levels (Fig. 1c)
following RYGB. UCP3 mRNA levels (Fig. 1d) were
decreased 12 months after surgery (p=0.03).
Simple regression analysis revealed a significant positive
relationship between PGC1A and MFN2 ( p<0.0001,
r2=0.53), as shown in Fig. 2. No significant relationship
linked CPT1 or UCP3 to PGC1A. UCP3 was positively
linked to BMI ( p=0.001, r2=0.22).
As shown in Fig. 3a, whole-body glucose uptake, assessed
by the clamp technique, was increased at 3 and 12 months
( p=0.002 and p=0.003 vs pre-op respectively). During the
test, both insulin-stimulated non-oxidative (Fig. 3b) and
oxidative (Fig. 3c) glucose utilisation, expressed as Δ from
baseline, were higher both at 3 and 12 months than pre-
operative values ( p=0.01 at 3 months and p=0.006 at
Table 1 Profile of several
anthropometric and metabolic
parameters, measured in
morbidly obese women during
the body weight loss process
induced by RYGB
Pre-operative values of the 11
patients (out of 17) tested at
12 months are reported in
parentheses
a p<0.05 to p<0.01
b p<0.005 to p<0.001
c p<0.0005 to p<0.0001 for
difference from pre-operative
values
Before RYGB (n=17) 3 months (n=17) 12 months
(n=11)
Body weight (kg) 124.4±13 (127.8±12) 102.2±12c 82.5±13c
BMI (kg/m2) 45.9±4 (46.1±3) 37.7±4c 30.5±5c
Plasma glucose (mmol/l) 5.8±1.1 (5.9±1.2) 4.9±0.4a 4.5±0.4a
Plasma insulin (pmol/l) 168.6±86 (170.3±86) 84.3±34c 56.8±34b
Energy expenditure (MJ/day) 8.28±0.4 (8.10±0.7) 6.80±0.8b 6.90±0.9b
Protein oxidation
(mg kg LMB−1 min−1)
0.79±0.3 (0.84±0.2) 0.46±0.13b 0.74±0.3
Glucose oxidation
(μmol kg LMB−1 min−1)
5.25±4.4 (5.45 ±2.8) 1.93±4.4 1.54±4.9a
Lipid oxidation
(mg kg LMB−1 min−1)
1.66±0.5 (1.52±0.3) 1.88±0.5 1.98±0.3
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Fig. 1 Modifications of skeletal muscle PGC1A (a), MFN2 (b), CPT1
(c) and UCP3 (d) expression during RYGB-induced weight loss. The
pre-operative values (arbitrary units [AU]) of the 11 patients (out of
17) tested at 12 months were: PGC1A 1.16±0.8; MFN2 1.24±0.9;
CPT1 115±0.8; UCP3 0.68±0.4. †p<0.05 to p<0.01 vs pre-operative
values
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12 months for non-oxidative glucose utilisation; p=0.04 at
3 months and p=0.02 at 12 months for oxidative glucose
utilisation). The inhibition of lipid oxidation was more
marked after surgery ( p=0.03 and p=0.002, respectively at
3 and 12 months; Fig. 3d). During the steady state of the
clamp, the RER varied consistently with these modifications
(Table 2). In fact, at all the time-points, euglycaemic hyper-
insulinaemia induced an increase in RER. This increase,
however, was more marked both at 3 and 12 months than
in the pre-operative conditions ( p=0.01 and p=0.002,
respectively).
Table 3 illustrates the variables that, in simple regression
analysis, showed a significant relationship with glucose up-
take, which was positively related to both PGC1A ( p=0.005)
and MFN2 ( p=0.0001) mRNA expression, whereas BMI
( p=0.0001) and UCP3 ( p=0.03) showed a negative rela-
tionship with glucose uptake. CPT1 mRNA was not related
to glucose uptake.
Multiple regression analysis (Table 4) showed that the
relationship between both PGC1A and UCP3 and glucose
uptake was no longer statistically significant when MFN2
and BMI were taken into account. Therefore, MFN2 and
BMI remained the significant and independent determinants
of glucose uptake (r2=0.48).
MFN2 mRNA was related to the glucose oxidation rate
measured during the clamp ( p=0.008; r2=0.16). CPT1 and
UCP3 were not related to energy expenditure or to fasting
lipid oxidation.
Discussion
The main results of this investigation are that, in muscle,
weight reduction upregulates expression of PGC1A (Fig. 1).
Second, this upregulation is associated with increased
expression of MFN2, which, in turn, may contribute to the
improvement of insulin sensitivity.
To our knowledge, this is the first report demonstrating
that, during weight reduction, muscle PGC1A is upregu-
lated and that this upregulation is strongly linked to the
increase in MFN2 mRNA expression.
In fact, an increase in skeletal muscle PGC1A and MFN2
in response to physical exercise has already been recognised
[7]. Here, we demonstrate that both PGC1A and MFN2 are
upregulated by weight reduction and that the modifications
of PGC1A account for over 50% of those of MFN2 (Fig. 2).
We therefore suggest that, during body weight loss, the up-
regulation of PGC1A induces increased expression of MFN2,
similarly to the situation during physical exercise.
After surgery, insulin sensitivity improves, as documented
by the increase of glucose uptake and the inhibition of lipid
oxidation during the clamp tests (Fig. 3). Consistent with
these modifications, the RER was more markedly increased
during the steady state of the clamp at both post-operative
time points (Table 2). This improvement was independently
influenced by both BMI and MFN2 expression, which
together accounted for about 50% of the modifications of
insulin sensitivity (Table 4). Similarly to our results, MFN2
was seen to be increased after massive weight loss induced
by another bariatric procedure, the biliopancreatic diversion
[33]. Interestingly, weight reduction obtained by this surgical
intervention is mainly based on malabsorption, namely of
fat. In contrast, RYGB leads to a reduced food intake, with a
particular restriction of carbohydrate [34], as strongly in-
dicated in our results by the low post-operative basal glucose
oxidation rate (Table 1). This suggests that diet composition
does not play a role in the stimulation of MFN2.
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Fig. 3 Glucose uptake (a), non-oxidative glucose utilisation (b),
glucose oxidation (c) and lipid oxidation (d) during hyperglycaemic–
hyperinsulinaemic clamp. Glucose and lipid oxidation were calculated
as Δ from basal conditions, before and after RYGB gastric bypass.
The pre-operative values of the ten patients (out of 17) submitted to
the clamp test at 12 months were: glucose uptake 20.7±11.6 μmol kg
LBM−1 min−1; non-oxidative glucose utilisation 15.3±11.6 μmol kg
LBM−1 min−1; Δ glucose oxidation 5.8±7.2 μmol kg LBM−1 min−1;
Δ lipid oxidation −0.35±0.2 mg kg LBM−1 min−1. †p<0.05 to p<
0.01, ††p<0.005 to p<0.001 vs pre-operative values
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Three months after the operation, protein oxidation was
markedly decreased. This result is in keeping with the pre-
viously reported reduction of protein utilisation during severe
restriction of energy intake [35].
In our study, we did not observe any significant modifica-
tion of CPT1 mRNA expression. This is in agreement with
previously reported findings [18, 36] after moderate weight
loss, demonstrating that even massive weight reduction is
without effect on CPT1 expression. In contrast to physical
exercise-mediated PGC1A upregulation, PGC1A upregula-
tion due to weight reduction was not associated with an
increase of CPT1 expression. The lack of CPT1 induction
could be explained by the fact that PGC1A requires the
intervention of other co-factors in order to increase mRNA
expression of its targets. These co-factors may be stimulated
(or not) according to specific physiopathological situations
and/or the tissues in question. For instance, liver PGC1A
enhances the stimulatory action of thyroid hormone on
CPT1 [37]. If the same mechanism regulates muscle CPT1,
the well documented decrease of thyroid function during
active weight loss process [38] could conceivably prevent an
increase of CPT1 expression.
The second aim of the present study was to investigate
whether CPT1 and/or UCP3 are involved in the modifica-
tions of energy expenditure and whole-body lipid oxidation
during weight reduction induced by gastric bypass.
As previously reported by our group, the massive weight
loss process following RYGB is accompanied by an energy
economy phenomenon, essentially due to a defect in lipid
oxidation. This phenomenon can impair the correction of
excess body weight [19].
In muscle, both CPT1 and UCP3 contribute to the con-
trol of lipid oxidation. Their downregulation, after weight
reduction, has been proposed as a possible reason for limited
weight loss and/or relapse to obesity [18, 23]. Skeletal muscle
is a major contributor to overall energy expenditure. There-
fore, it was logical to expect that the modifications of CPT1
and/or UCP3 could, at least in part, explain those of whole-
body energy expenditure.
Contrary to this hypothesis, CPT1 and UCP3 mRNA
expression did not show any significant relationship with
post-operative energy expenditure or lipid oxidation. The
biological activity of these factors was not measured in the
present study. We cannot, therefore, rule out the possibility
that muscle CPT1 and UCP3 have an impact on overall
energy balance during weight loss. Two points, however,
should be considered: first, the studies in which both mRNA
expression and activity were measured demonstrate that in
general these two parameters consistently vary [39]. Second,
and even more convincingly, the only study investigating
CPT1 activity and energy expenditure, both at the muscle
level, failed to find any relationship between CPT1 activity
and energy expenditure, even when the latter is measured
locally [40].
A recent hypothesis on the physiological role of UCP3
could help interpret the decrease in UCP3 expression during
weight loss [41]. In fact, based on in vitro experiments,
UCP3 has been proposed to be a factor that limits reactive
oxygen species (ROS) production by facilitating fatty acid
oxidation [41]. Thus, the role of UCP3 would be to protect
muscle tissue against lipotoxicity, rather than to regulate
energy expenditure. Schrauwen et al. [42] have suggested
Table 2 Variations of the respiratory exchange rate, measured in
fasting conditions and during the steady state of the euglycaemic–
hyperinsulinaemic clamp
Before RYGB 3 months after
RYGB
12 months after
RYGB
Fasting 0.78±0.05
(0.78±0.06)
0.75±0.04 0.75±0.04
Clamp 0.82±0.05
(0.81±0.05)
0.82±0.06 0.86±0.06
Δ 0.04±0.03
(0.03±0.03)
0.07±0.04a 0.11±0.04b
Pre-operative values of the 11 patients (out of 17) tested at 12 months
are reported in parentheses
a p<0.05 to p<0.01
b p<0.005 to p<0.001 for difference from pre-operative values
Table 3 Synthesis of simple regression analyses of BMI and muscle
molecular parameters vs insulin sensitivity measured before and
during RYGB-induced weight loss
Independent variable Dependent variable
Glucose uptake
p value r2
PGC1A 0.005 0.17
MFN2 0.0001 0.29
UCP3 0.03 –0.10
BMI 0.0001 –0.29
Table 4 Multiple regression analysis of factors influencing insulin
sensitivity, i.e. glucose uptake
Independent variable Dependent variable
Glucose uptake
p value R2
PGC1A NS 0.48
MFN2 0.006 0.48
UCP3 NS 0.48
BMI 0.002 0.48
There was a significant and independent relationship of BMI (p=
0.002) and MFN2 (p=0.006) with insulin sensitivity measured in
morbidly obese women before and during RYGB-induced weight loss
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that UCP3 could contribute to outward translocation of
NEFA, occurring when NEFA availability exceeds mito-
chondrial oxidative capacity. This mechanism would protect
the mitochondria from NEFA accumulation. According to
this hypothesis, the UCP3 downregulation after weight loss
could result from a reduced need for NEFA exportation from
the mitochondrial matrix. Finally, UCP3 expression is pow-
erfully regulated by intramyocellular triacylglycerol content
[24]. Therefore, the decrease in UCP3 expression with
decreasing BMI could be due to muscular triacylglycerol
depletion and to the reduced lipotoxicity resulting from that
depletion.
In conclusion, our study shows that massive weight loss
upregulates PGC1A mRNA expression in skeletal muscle.
This increase is associated with enhanced MFN2 expres-
sion, which contributes to the amelioration of insulin sen-
sitivity. CPT1 or UCP3 mRNA expression does not show
any significant impact on the modifications of insulin sen-
sitivity or on the regulation of energy expenditure.
Further studies are needed to identify co-factors that have
a permissive role for PGC1A in the stimulation of its targets
and to determine whether these co-factors are specifically
activated in different physiopathological conditions.
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